Tus kws kho mob
Copy of providers-COVID19_FAQ_8-6-2020.pdf
Tshawb Nrhiav
Nthuav pom cov txiaj ntsig tshwm sim 2091 - 2100 ntawm 4204
Tus kws kho mob
Upcoming policies effective October 5, 2020
Tus kws kho mob
Reduction Mammoplasty Commercial Pre-Authorization Request Form (Medical Policy IV-32) (PDF)
Tus kws kho mob
P28R1-20 Update: Medical Oncology Drug Prior Authorization Updates for Fully Insured Commercial and Medicare Advantage Subscribers – eviCore Healthcare Specialty Utilization Management (UM) Program
Hnub Tim pib siv tau lub khoos kas: Lub Yim Hlis Ntuj Tim 03, 2020
Tus kws kho mob
P57-20 Site of Service Program Updates for Selected Specialty Medical Drugs for Commercial Subscribers: Medical Policy XI-06
Hnub Tim pib siv tau lub khoos kas: Lub Yim Hlis Ntuj Tim 03, 2020
Tus kws kho mob
P63-20 Prior Authorization Updates for Skilled Nursing Facility Admissions
Hnub Tim pib siv tau lub khoos kas: Lub Yim Hlis Ntuj Tim 03, 2020
Tus kws kho mob
P55-20 New Prior Authorization Timeframes Required by Legislation
Hnub Tim pib siv tau lub khoos kas: Lub Yim Hlis Ntuj Tim 03, 2020
Tus kws kho mob
P58-20 Hereditary Angioedema (HAE) Drug Prior Authorization Management Changes for generic Icatibant, Firazyr, Haegarda, and Takhzyro — Effective October 5, 2020
Hnub Tim pib siv tau lub khoos kas: Lub Yim Hlis Ntuj Tim 03, 2020
Tus kws kho mob
P56-20 New Medical, Medical Drug and Behavioral Health Policy Management Updates—Effective October 5, 2020
Hnub Tim pib siv tau lub khoos kas: Lub Yim Hlis Ntuj Tim 03, 2020
Tus kws kho mob
P33-20 Billing Change for Board Certified Behavioral Analysts
Hnub Tim pib siv tau lub khoos kas: Lub Tsib Hlis Ntuj Tim 01, 2020